LIQUIDITY	6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY	LIQUIDITY These unaudited interim consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $55,337 in accumulated deficit through June 30, 2026. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of June 30, 2026, the Company had cash and cash equivalents of approximately $10,947. On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright & Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $10.0 million of shares of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement. As of June 30, 2026, the Company has sold 1,748,549 shares of Common Stock in the ATM Offering at a weighted-average price of $8.22 per share, raising $14,379 of gross proceeds and net proceeds of $13,708, after deducting commissions to the sales agent and other ATM Offering related expenses. On January 30, 2026, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $60,000, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $12,639 that were sold under the ATM Offering through January 29, 2026, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3. On April 1, 2025, the Company entered into a securities purchase agreement (the April 2025 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants, in a public offering (the April 2025 Offering), for net proceeds of $4,020, after deducting offering expenses of $979. On December 11, 2025, the Company entered into a securities purchase agreement (the December 2025 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants, in a public offering (the December 2025 Offering), for net proceeds of $6,288 after deducting offering expenses of $1,711. Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its currently planned operating expenses and capital expenditure requirements through the second quarter of 2027. However, this estimate assumes that the Company only continues the preliminary work towards the initiation of additional clinical studies of GRI-0621; the Company would not be able to complete the additional dose-ranging and other clinical studies for GRI-0621, which will require substantial additional capital or resources. The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements and potentially through strategic partner and collaboration agreements, but there can be no assurances any such financing will be available when needed, even if the Company’s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements. These unaudited interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty. Separately, on July 22, 2026, the SEC’s Division of Trading and Markets, acting under delegated authority, approved a new Nasdaq continued listing requirement (the “MVLS Requirement”) under which companies listed on The Nasdaq Capital Market must maintain a Market Value of Listed Securities (“MVLS”) of at least $5,000. On July 29, 2026, the SEC stayed the approval order after receiving petitions for Commission-level review pursuant to Rule 431(e) of the SEC’s Rules of Practice, and the MVLS Requirement is not currently in effect. If the MVLS Requirement becomes effective, a company whose MVLS remains below $5,000 for 30 consecutive business days would be subject to immediate suspension from trading and delisting proceedings, with no cure or compliance period to stay the suspension of trading. A company may appeal the delisting determination to the Nasdaq Hearings Panel (the Hearings Panel), but a timely request for a hearing will not automatically stay the suspension of trading. The Hearings Panel may, in its discretion, grant an exception of up to 180 days for the company to demonstrate compliance with The Nasdaq Capital Market’s initial listing requirements. As of the date of this Quarterly Report, the Company’s MVLS is less than $5,000. If the MVLS Requirement becomes effective and the Company’s Common Stock is suspended from trading or delisted from The Nasdaq Capital Market, this could further impair the Company’s ability to raise additional capital and impact the Company’s ability to continue as a going concern.

These unaudited interim consolidated financial statements have been prepared on the basis that the Company is a going concern, which contemplates, among other things, the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has not generated any significant revenues from operations since inception and does not expect to do so in the foreseeable future. The Company has incurred operating losses since its inception in 2009 and as a result has incurred $55,337 in accumulated deficit through June 30, 2026. The Company has financed its working capital requirements to date through the issuance of equity and debt securities. As of June 30, 2026, the Company had cash and cash equivalents of approximately $10,947.

On May 20, 2024, the Company entered into an At The Market Offering Agreement (the Sales Agreement) with H.C. Wainwright & Co., LLC (Wainwright), pursuant to which the Company may sell and issue, subject to the limitations in the Sales Agreement, up to $10.0 million of shares of Common Stock from time to time through Wainwright as its sales agent (the ATM Offering). Under the Sales Agreement, Wainwright is entitled to compensation of 3.0% of the gross offering proceeds of all shares of Common Stock sold through it pursuant to the Sales Agreement. As of June 30, 2026, the Company has sold 1,748,549 shares of Common Stock in the ATM Offering at a weighted-average price of $8.22 per share, raising $14,379 of gross proceeds and net proceeds of $13,708, after deducting commissions to the sales agent and other ATM Offering related expenses.

On January 30, 2026, the Company filed a prospectus supplement to its registration statement on Form S-3 (File No. 333-279348) to increase the amount of shares of Common Stock that the Company may offer and sell under the Sales Agreement and applicable registration statement to an aggregate offering price of up to $60,000, which amount does not include the shares of Common Stock having an aggregate gross sales price of approximately $12,639 that were sold under the ATM Offering through January 29, 2026, in accordance with the limitations set forth in Instruction I.B.6 of Form S-3.

On April 1, 2025, the Company entered into a securities purchase agreement (the April 2025 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants, in a public offering (the April 2025 Offering), for net proceeds of $4,020, after deducting offering expenses of $979.

On December 11, 2025, the Company entered into a securities purchase agreement (the December 2025 Purchase Agreement), pursuant to which the Company issued and sold Common Stock, pre-funded warrants and common warrants, in a public offering (the December 2025 Offering), for net proceeds of $6,288 after deducting offering expenses of $1,711.

Based on the Company’s current operating plan, the Company believes that its existing cash and cash equivalents will be sufficient to fund its currently planned operating expenses and capital expenditure requirements through the second quarter of 2027. However, this estimate assumes that the Company only continues the preliminary work towards the initiation of additional clinical studies of GRI-0621; the Company would not be able to complete the additional dose-ranging and other clinical studies for GRI-0621, which will require substantial additional capital or resources.

The Company’s ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program. The Company intends to raise capital through additional issuances of equity securities and/or short-term or long-term debt arrangements and potentially through strategic partner and collaboration agreements, but there can be no assurances any such financing will be available when needed, even if the Company’s research and development efforts are successful. If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely. Therefore, there is substantial doubt about the Company’s ability to continue as a going concern for a period of one year from the issuance of these unaudited interim consolidated financial statements. These unaudited interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Separately, on July 22, 2026, the SEC’s Division of Trading and Markets, acting under delegated authority, approved a new Nasdaq continued listing requirement (the “MVLS Requirement”) under which companies listed on The Nasdaq Capital Market must maintain a Market Value of Listed Securities (“MVLS”) of at least $5,000. On July 29, 2026, the SEC stayed the approval order after receiving petitions for Commission-level review pursuant to Rule 431(e) of the SEC’s Rules of Practice, and the MVLS Requirement is not currently in effect. If the MVLS Requirement becomes effective, a company whose MVLS remains below $5,000 for 30 consecutive business days would be subject to immediate suspension from trading and delisting proceedings, with no cure or compliance period to stay the suspension of trading. A company may appeal the delisting determination to the Nasdaq Hearings Panel (the Hearings Panel), but a timely request for a hearing will not automatically stay the suspension of trading. The Hearings Panel may, in its discretion, grant an exception of up to 180 days for the company to demonstrate compliance with The Nasdaq Capital Market’s initial listing requirements. As of the date of this Quarterly Report, the Company’s MVLS is less than $5,000. If the MVLS Requirement becomes effective and the Company’s Common Stock is suspended from trading or delisted from The Nasdaq Capital Market, this could further impair the Company’s ability to raise additional capital and impact the Company’s ability to continue as a going concern.